Relief Therapeutics Holding SA

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP

N/A
SEDOL

N/A
CIK

N/A

relieftherapeutics.com
LEI: 506700IT19260EVD7916
FIGI: BBG000C4N8Q6
RLF

Relief Therapeutics Holding SA
GICS: - · Sektor: - · Sub-Sektor: -
AI
PROFILER
NAME
Relief Therapeutics Holding SA
ISIN
CH1251125998
TICKER
RLF
MIC
XSWX
REUTERS
RLF.S
BLOOMBERG
RLF SW
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von ACCESS Newswire bereitgestellt.
Di., 11.02.2025       Relief Therapeutics
CH1251125998

Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment GENEVA, SWITZERLAND / ACCESS Newswire / February 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rar...
Mi., 22.01.2025       Relief Therapeutics
CH1251125998

Sale of GOLIKE® Rights Outside the U.S. to NutrisensRelief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products GENEVA, SWITZERLAND / ACCESS Newswire / January 22, 2025 / RELIEF THERAPEUTICS Holding SA(SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering in...
Fr., 27.12.2024       Relief Therapeutics
CH1251125998

GENEVA, SWITZERLAND / ACCESSWIRE / December 27, 2024 / RELIEF THERAPEUTICS Holding SA(SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today provided an update on the potential reverse merger with Renexxion, In...
Mo., 16.12.2024       Relief Therapeutics
CH1251125998

Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PKU PatientsResults Expected to Promote Awareness and Adoption of PKU GOLIKE ®GENEVA, SWITZERLAND / ACCESSWIRE / December 16, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF )(OTCQB:RLFTF )(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company commi...
Fr., 13.12.2024       Relief Therapeutics
CH1251125998

Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB QuotationGENEVA, SWITZERLAND / ACCESSWIRE / December 13, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and...
Mo., 11.11.2024       Relief Therapeutics
CH1251125998

GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced positive final results from its proof-of-concept, investig...
Mo., 04.11.2024       Relief Therapeutics
CH1251125998

GENEVA, SWITZERLAND / ACCESSWIRE / November 4, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it has signed a non-binding letter of intent (LOI) with Ren...
Di., 29.10.2024       Relief Therapeutics
CH1251125998

GENEVA, SWITZARLAND / ACCESSWIRE / October 29, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced the publication of a Plain Language Summary in Future Rare Diseas...
Fr., 25.10.2024       Relief Therapeutics
CH1251125998

New Study Results Indicate Superior Absorption of RLF-OD032 in Fasted State Compared to KUVAN®, Potentially Enabling Flexible Dosing Options GENEVA, SWITZERLAND / ACCESSWIRE / October 25, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innov...
Di., 08.10.2024       Relief Therapeutics
CH1251125998

GENEVA, SWITZERLAND / ACCESSWIRE / October 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced promising preliminary results from its proof-of-concept, inv...
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S